Zill-E-Huma Latif

440 total citations
12 papers, 328 citations indexed

About

Zill-E-Huma Latif is a scholar working on Public Health, Environmental and Occupational Health, Epidemiology and Pharmacology. According to data from OpenAlex, Zill-E-Huma Latif has authored 12 papers receiving a total of 328 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Public Health, Environmental and Occupational Health, 9 papers in Epidemiology and 3 papers in Pharmacology. Recurrent topics in Zill-E-Huma Latif's work include Opioid Use Disorder Treatment (12 papers), Substance Abuse Treatment and Outcomes (9 papers) and Prenatal Substance Exposure Effects (3 papers). Zill-E-Huma Latif is often cited by papers focused on Opioid Use Disorder Treatment (12 papers), Substance Abuse Treatment and Outcomes (9 papers) and Prenatal Substance Exposure Effects (3 papers). Zill-E-Huma Latif collaborates with scholars based in Norway, Puerto Rico and Bangladesh. Zill-E-Huma Latif's co-authors include Kristin Klemmetsby Solli, Lars Tanum, Arild Opheim, Nikolaj Kunøe, Jūratė Šaltytė Benth, Peter Krajči and Lars Thore Fadnes and has published in prestigious journals such as Biological Psychiatry, Addiction and JAMA Psychiatry.

In The Last Decade

Zill-E-Huma Latif

12 papers receiving 319 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Zill-E-Huma Latif Norway	7	271	221	75	54	51	12	328
Arild Opheim Norway	8	282 1.0×	231 1.0×	77 1.0×	54 1.0×	51 1.0×	17	354
Kristin Klemmetsby Solli Norway	10	329 1.2×	265 1.2×	83 1.1×	61 1.1×	62 1.2×	30	406
Oscar D’Agnone United Kingdom	8	199 0.7×	145 0.7×	46 0.6×	63 1.2×	52 1.0×	15	296
Mirsada Serdarevic United States	7	197 0.7×	97 0.4×	97 1.3×	59 1.1×	60 1.2×	15	335
Thilo Beck Switzerland	10	190 0.7×	178 0.8×	37 0.5×	89 1.6×	31 0.6×	12	360
Wolfgang Gombas Austria	8	300 1.1×	188 0.9×	108 1.4×	77 1.4×	47 0.9×	11	370
Alfonso Ang United States	8	204 0.8×	184 0.8×	74 1.0×	45 0.8×	45 0.9×	10	336
Kaitlyn Mishlen United States	8	216 0.8×	165 0.7×	74 1.0×	111 2.1×	25 0.5×	11	293
Jean Falcioni United States	7	237 0.9×	172 0.8×	58 0.8×	83 1.5×	38 0.7×	8	336
Meng-Fan Su China	5	232 0.9×	195 0.9×	77 1.0×	25 0.5×	28 0.5×	6	321

Countries citing papers authored by Zill-E-Huma Latif

Since Specialization

Citations

This map shows the geographic impact of Zill-E-Huma Latif's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zill-E-Huma Latif with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zill-E-Huma Latif more than expected).

Fields of papers citing papers by Zill-E-Huma Latif

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zill-E-Huma Latif. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zill-E-Huma Latif. The network helps show where Zill-E-Huma Latif may publish in the future.

Co-authorship network of co-authors of Zill-E-Huma Latif

This figure shows the co-authorship network connecting the top 25 collaborators of Zill-E-Huma Latif. A scholar is included among the top collaborators of Zill-E-Huma Latif based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zill-E-Huma Latif. Zill-E-Huma Latif is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

12 of 12 papers shown

Opheim, Arild, Kristin Klemmetsby Solli, Zill-E-Huma Latif, et al.. (2021). Risk of Relapse Among Opioid‐Dependent Patients Treated With Extended‐Release Naltrexone or Buprenorphine‐Naloxone: A Randomized Clinical Trial. American Journal on Addictions. 30(5). 453–460. 4 indexed citations

Solli, Kristin Klemmetsby, Arild Opheim, Zill-E-Huma Latif, et al.. (2020). Adapting treatment length to opioid‐dependent individuals’ needs and preferences: a 2‐year follow‐up to a 1‐year study of extended‐release naltrexone. Addiction. 116(8). 2084–2093. 10 indexed citations

Solli, Kristin Klemmetsby, Nikolaj Kunøe, Zill-E-Huma Latif, et al.. (2019). Availability of Extended-Release Naltrexone May Increase the Number of Opioid-Dependent Individuals in Treatment: Extension of a Randomized Clinical Trial. European Addiction Research. 25(6). 303–309. 9 indexed citations

Tanum, Lars, Zill-E-Huma Latif, Kristin Klemmetsby Solli, et al.. (2019). T212. No Increase in Chronic Pain Among Opioid-Dependent Individuals Randomized to Treatment With Extended-Release Naltrexone Compared to Buprenorphine-Naloxone. Biological Psychiatry. 85(10). S211–S212. 1 indexed citations

Latif, Zill-E-Huma, Kristin Klemmetsby Solli, Arild Opheim, et al.. (2019). No increased pain among opioid‐dependent individuals treated with extended‐release naltrexone or buprenorphine‐naloxone: A 3‐month randomized study and 9‐month open‐treatment follow‐up study. American Journal on Addictions. 28(2). 77–85. 23 indexed citations

Tanum, Lars, Kristin Klemmetsby Solli, Zill-E-Huma Latif, et al.. (2018). S273. The Effectiveness of Injectable Extended Release Naltrexone Versus Daily Buprenorphine-Naloxone for Opioid Dependence in Short and Long Term Treatment. Biological Psychiatry. 83(9). S454–S454. 4 indexed citations

Latif, Zill-E-Huma, Jūratė Šaltytė Benth, Kristin Klemmetsby Solli, et al.. (2018). Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone. JAMA Psychiatry. 76(2). 127–127. 46 indexed citations

Solli, Kristin Klemmetsby, Zill-E-Huma Latif, Arild Opheim, et al.. (2018). Effectiveness, safety and feasibility of extended‐release naltrexone for opioid dependence: a 9‐month follow‐up to a 3‐month randomized trial. Addiction. 113(10). 1840–1849. 24 indexed citations

Tanum, Lars, Kristin Klemmetsby Solli, Zill-E-Huma Latif, et al.. (2017). Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence. JAMA Psychiatry. 74(12). 1197–1197. 178 indexed citations

10.

Tanum, Lars, et al.. (2017). Optimal prevention of relapse among opioid users: A 12-week randomized controlled trial of extended-release naltrexone injections versus daily buprenorphine-naloxone. Drug and Alcohol Dependence. 171. e200–e201. 1 indexed citations

11.

Kunøe, Nikolaj, et al.. (2016). Interest in Extended Release Naltrexone among Opioid Users. European Addiction Research. 22(6). 301–305. 6 indexed citations

12.

Kunøe, Nikolaj, et al.. (2016). Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX). BMC Pharmacology and Toxicology. 17(1). 18–18. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact